Avantor (NYSE:AVTR) Price Target Lowered to $25.00 at Morgan Stanley

Avantor (NYSE:AVTR) had its target price reduced by Morgan Stanley from $27.00 to $25.00 in a report issued on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus reduced their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. Wells Fargo & Company reduced their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Monday. UBS Group restated a “neutral” rating and issued a $25.00 target price (down previously from $29.00) on shares of Avantor in a research note on Friday, January 17th. Royal Bank of Canada reduced their price target on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating on the stock in a research report on Monday. Finally, Barclays reduced their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a research report on Monday. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Avantor presently has an average rating of “Moderate Buy” and an average price target of $26.15.

Avantor Stock Down 1.8 %

AVTR opened at $18.06 on Monday. Avantor has a fifty-two week low of $18.00 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm’s fifty day moving average price is $21.63 and its two-hundred day moving average price is $23.39. The company has a market capitalization of $12.29 billion, a P/E ratio of 39.26, a P/E/G ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, February 12th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the prior year, the firm posted $0.22 EPS. On average, analysts anticipate that Avantor will post 0.98 EPS for the current year.

Institutional Trading of Avantor

A number of institutional investors and hedge funds have recently modified their holdings of the stock. ExodusPoint Capital Management LP bought a new stake in shares of Avantor in the 4th quarter valued at about $13,368,000. Westpac Banking Corp increased its stake in shares of Avantor by 14.3% in the 4th quarter. Westpac Banking Corp now owns 9,650 shares of the company’s stock valued at $203,000 after acquiring an additional 1,207 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Avantor by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 11,232,329 shares of the company’s stock valued at $236,227,000 after acquiring an additional 81,541 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Avantor by 1.6% in the 4th quarter. Franklin Resources Inc. now owns 1,150,929 shares of the company’s stock valued at $24,250,000 after acquiring an additional 17,598 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in Avantor by 15.1% during the 4th quarter. Alliancebernstein L.P. now owns 4,891,475 shares of the company’s stock worth $103,063,000 after purchasing an additional 640,881 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.